© 2018 Miraculo Inc. All Rights Reserved
The endocannabinoid system as a target for the treatment of motor dysfunction
Cannabinoids are a group of chemicals that come from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have suggest that it has anti inflammatory effects when induced in animals. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychotropic effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to bind and do their job in the body. In this paper, available data is looked at relating to the interaction between the cannabinoid system and basal ganglia activity, both in healthy and pathological syndromes and will also look at future lines of study expected to increase recent knowledge about the possible therapeutic advantages of targeting this site in parkinson’s, huntington’s and basal ganglia disorders.
Cannabinoids can have benefits for motor dysfunction
There is knowledge that cannabinoid based products that are specific for different sites in the cannabinoid signalling system might be good in basal ganglia disorders, especially Parkinson’s disease (PD) and Huntington’s disease (HD). These advantages do not only involve the reducing of specific motor symptoms, but also the halt the disease progression due to the neuroprotective abilities illustrated in cannabinoids. More so, a lot of biochemical, anatomical, physiological and pharmacological research has seen that the different types of cannabinoid system are plenty in basal ganglia structures and they are impacted by these disorders; the cannabinoid system plays a main role in basal ganglia function by changing the neurotransmitters that workin the basal ganglia circuits, both in healthy and pathological syndromes; and the reducing and/or inhibition of the cannabinoid system is related with detrimental motor responses that are maintained and even increased in conditions of malfunctioning and motor dysfunctionFern-ndez-Ruiz-2009-British_Journal_of_Pharmacology-1